 | Up a level |
Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Gorlov, J. S., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Levis, A., Krause, S., Schmoll, H. J., Hertenstein, B., Zaccaria, A., Guarini, A., Atta, J., Bassan, R., Cervetti, J., Elter, T., Enggaard, L., Haenel, M., Kneba, M., Liberati, M., Martelli, M., Martens, U., Morra, E., Pinto, A., Zaja, F., Ponzoni, M., Deckert, M., Politi, L. S., Finke, J., Reni, M., Cavalli, F., Zucca, E. and Illerhaus, G. (2017). Autologous stem cell transplantation (ASCT) or whole-brain radiotherapy (WBRT) as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary cns lymphoma (PCNSL): results of the IELSG32 randomized Phase II Trial. Bone Marrow Transplant., 52. S. S96 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Fritsch, K., Kasenda, B., Schorb, E., Hau, P., Bloehdorn, J., Moehle, R., Loew, S., Binder, M., Atta, J., Keller, U., Wolf, H-H, Krause, S. W., Hess, G., Naumann, R., Sasse, S., Hirt, C., Lamprecht, M., Martens, U., Morgner, A., Panse, J., Frickhofen, N., Roeth, A., Hader, C., Deckert, M., Fricker, H., Ihorst, G., Finke, J. and Illerhaus, G. (2017). High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia, 31 (4). S. 846 - 853. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Illerhaus, G., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L. S., Fox, C. P., La Rose, P., Ambrosetti, A., Roeth, A., Hemmaway, A., Ilariucci, F., Linton, K. M., Soffietti, R., Pukrop, T., Binder, M., Balzarotti, M., Fabbri, A., Johnson, P., Gorlov, J. S., Cavalli, F., Finke, J., Schorb, E., Reni, M., Zucca, E. and Ferrer, A. J. M. (2015). Improved outcome with addition of thiotepa and rituximab to methotrexate and cytarabine in primary cns lymphoma: Results of the first randomization of the IELSG-32 trial. Oncol. Res. Treat., 38. S. 177 - 178. BASEL: KARGER. ISSN 2296-5262